Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 4

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 4
---
 Information on how to vote in person at the meeting is discussed below. Who can vote at the meeting? Only shareholders of record at the close of business on April 17, 2025 will be entitled to vote at the meeting. On this record date, there were 36,193,479 shares of common stock outstanding and entitled to vote. Shareholder of Record: Shares Registered in Your Name : If on the record date your shares were registered directly in your name with Armata’s transfer agent, Computershare, Inc., then you are a shareholder of record. As a shareholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the annual meeting, we urge you to vote your shares by completing, signing and returning the enclosed proxy card, or following the instructions on the enclosed proxy card to submit your proxy to vote your shares via telephone or on the internet. Beneficial Owner: Shares Registered in the Name of a Broker or Bank : If on the record date your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and our proxy materials are being forwarded to you by that organization. The broker, bank, or other agent holding your account is considered to be the shareholder of record for purposes of voting at the meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the meeting. However, since you are not the shareholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker, bank, or other agent. What am I voting on? There are three matters scheduled for a vote: • Proposal 1 : To elect seven nominees for director, named in this Proxy Statement, to serve one-year terms expiring at the 2026 Annual Meeting of Shareholders and upon their successors being duly elected and qualified; • Proposal 2 : To approve, on an advisory, non-binding basis, the compensation of our named executive officers; and • Proposal 3 : To ratify the Audit Committee’s selection of Ernst & Young LLP (“ Ernst & Young ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. What if another matter is properly brought before the meeting? The Board of Directors